Question
MR vaccine
Answer
MR vaccine is a combination live attenuated vaccine protecting against Measles and Rubella — a two-component version of the more familiar MMR vaccine, omitting the mumps component.
Rationale for use: in national immunization programmes (including India’s, where MR vaccine has replaced the earlier monovalent measles vaccine in the primary schedule), MR vaccine is used where the primary public health priority is measles elimination and prevention of congenital rubella syndrome, without necessarily needing to include mumps coverage in the same campaign/programme (mumps generally causes less severe population-level morbidity than measles or congenital rubella, so some national programmes have prioritized MR over full MMR, particularly during large-scale catch-up campaigns).
Schedule: given as part of routine immunization — in India’s Universal Immunization Programme, MR vaccine doses are given at 9–12 months and 16–24 months of age, having replaced the earlier monovalent measles-only schedule; large-scale MR catch-up campaigns have also been conducted targeting a wider age range of children/adolescents to rapidly boost population immunity and accelerate measles elimination and rubella/congenital rubella syndrome control.
Composition and mechanism: live attenuated measles and rubella virus strains, inducing durable humoral and cell-mediated immunity, similar in principle to MMR.
Contraindications: pregnancy (theoretical risk from live rubella component) and significant immunosuppression.
Public health significance: central to India’s and other countries’ measles elimination and rubella/congenital rubella syndrome (CRS) elimination goals, with MR vaccination campaigns specifically designed to rapidly raise population immunity thresholds required to interrupt transmission of both viruses.